| Market Capitalization (Millions $) |
507 |
| Shares
Outstanding (Millions) |
41 |
| Employees |
75 |
| Revenues (TTM) (Millions $) |
215 |
| Net Income (TTM) (Millions $) |
133 |
| Cash Flow (TTM) (Millions $) |
26 |
| Capital Exp. (TTM) (Millions $) |
4 |
Entrada Therapeutics Inc
Entrada Therapeutics Inc is a clinical-stage biotechnology company that is dedicated to developing transformative therapeutics for various serious diseases. The company's technology platform is focused on utilizing the body's natural cellular uptake mechanisms to deliver large macromolecules, such as proteins and nucleic acids, across biological barriers for targeted intracellular delivery.
Founded in 2018, Entrada Therapeutics is headquartered in Boston, Massachusetts, in the United States, with additional offices in San Diego, California. The company is led by a team of seasoned industry executives, including CEO Dipal Doshi, President and COO Meghna Dasgupta, and CMO James Hamilton.
The company's lead program, ENTR-101, is a potential treatment for cystic fibrosis. ENTR-101 utilizes Entrada's proprietary Endosomal Escape Vehicle (EEV) technology to transport a specially designed protein that corrects the underlying genetic mutation causing cystic fibrosis. This technology allows the protein to enter the cell, bypass molecular barriers and reach its target in the endosome, thus enabling the protein to be fully functional.
In addition to ENTR-101, Entrada has a robust pipeline that includes multiple therapeutic programs in various stages of development. The company is focused on developing therapies for indications where macromolecular therapeutics have the potential to provide significant patient benefit, such as neurodegenerative diseases, genetic disorders, and cancer.
Entrada Therapeutics has developed strategic collaborations with key partners in the biotech industry, including Roche, Ferring Pharmaceuticals, and BMS. These partnerships provide the company with additional funding and resources, as well as important guidance and expertise.
Overall, Entrada Therapeutics is committed to bringing innovative, life-changing therapies to patients in need, by harnessing the power of its unique technology platform and scientific expertise. Their work is poised to have a profound impact on the lives of patients suffering from serious diseases.
Company Address: One Design Center Place Boston 2210 MA
Company Phone Number: 520-9158 Stock Exchange / Ticker: NASDAQ TRDA
|
5.05% 